Four multitransfused patients with severe aplastic anaemia (SAA) are described. Two received a BMT after conditioning with cyclophosphamide (Cy) plus antithymocyte globulin (ATG). Both suffered a graft failure (GF) and had a second transplant with PBSC from the original donor. Two other patients received a PBSCT as a first option, with Cy as the only conditioning drug. The four patients received methotrexate (MTX) and cyclosporine (CYA) as post-grafting immunosuppression. The two BMT patients with GF were successfully rescued with a PBSC second transplant. In the two cases where a PBSCT was done as a first option no GF was observed and a successful and complete haematological recovery was achieved. In conclusion, PBSCT rescued two SAA patients with GF after BMT. PBSCT without ATG as a first option produced a quick and complete haematological recovery in two additional patients, suggesting that PBSCT without ATG can be an alternative to BMT plus ATG in SAA as a first transplant option.
BMT is the therapy of choice for patients with severe aplastic anaemia (SAA) who have an HLA-compatible donor. A sub-group of patients who meet the criteria for very severe aplastic anaemia have a particularly unfavourable prognosis, requiring a more aggressive supportive therapy and, if a donor is available, an immediate transplant. 1, 2 Mexico is a country with a large number of cases of SAA. 3, 4 However, due to financial as well as idiosyncratic factors, the time elapsing from diagnosis to BMT is prolonged, which leads to our SAA patients being multitransfused and highly sensitised to HLA antigens long before the transplant is undertaken. In addition, although the level has declined from 35% to 9% since the 1970s, graft failure (GF) remains an obstacle to a successful BMT in SAA, with a higher risk for multitransfused patients. 5 Addition of antithymocyte globulin (ATG) to cyclophosphamide (Cy) during the 6 but the cost of ATG is beyond the majority of our mainly uninsured patients. On the other hand, PBSCT for different haematological pathologies is being used with increasing frequency. Several advantages over BMT are now acknowledged 7 and its use in AA appears to be increasing, although its superiority over BMT has not yet been clearly established.
We report our transplant experience with four longstanding, multitransfused SAA patients, who had no response to previous pharmacologic treatment including androgens, prednisone, cyclosporine (CYA), erythropoietin, and a 2-week short trial with granulocyte colony-stimulating factor (G-CSF); identifiable causes for their disease were ruled out. All the transplants were from HLA and blood group-identical siblings. Patient characteristics at presentation, post-transplant evolution and current status are summarised in Tables 1 and 2 . 8 with a short course of MTX and CYA at standard doses as prophylaxis for graft-versus-host disease (GVHD). She received a bone marrow infusion of 3 × 10 8 mononuclear cells (MNC)/kg of body weight. By day +15 her absolute neutrophil count (ANC) reached 500/l; platelet production began on day +20. On day +24 she was discharged without complications. Two months later the patient was admitted with pancytopenia; a bone marrow aspirate (BMA) showed an empty marrow and a diagnosis of GF was established. Four months later her donor was recalled and, after subcutaneous filgrastim mobilisation at 5 g/kg/5 days (total dose 25 g/kg), a PBSCT was performed with a product containing 12 × 10 8 MNC/kg. By day +17 engraftment was complete and she was discharged. For the past 3 years she has been healthy and her haematological recovery is complete.
Case 2
A repeatedly transfused 33-year-old woman was diagnosed with SAA 10 months before being referred for BMT evaluation. She had been in a high transfusion requirement regimen with her condition worsening over the previous months. A compatible donor was found in her immediate family and, after conditioning and GVHD prophylaxis regimens similar to case number 1, she received a BMT infusion containing 4 × 10 8 MNC/kg of body weight. A BMA was done on day +35, because of the delay to reach appropriate peripheral blood cell counts, and showed an empty marrow. GF was diagnosed. She received a second conditioning regimen, exclusively with ATG, and a PBSCT from the same cytokine-mobilised donor was performed. The product infused contained 14 × 10 8 MNC/kg. Her immediate recovery was uneventful and by day +7 ANC reached 500/l, a platelet count Ͼ20 000/l was documented on day +10, and she was discharged on day +14. Her course was remarkably good but 4 weeks later she developed cytomegalovirus pneumonia and died with an apparently normally functioning bone marrow.
Case 3
A 13-year-old boy with SAA diagnosed in 1994 was referred to our institution in May 1997 for allogeneic BMT as an unusual case of long-standing SAA, complicated with multiple red blood cell alloantibodies, platelet refractoriness, transfusion-related haemochromatosis and hepatosplenomegaly, secondary to transfusion of over 100 PRBC units. Based on the two previous experiences, a PBSCT was chosen over BMT as the transplant modality. The conditioning regimen consisted exclusively of Cy 50 mg/kg/4 days (total dose 200 mg/kg), without ATG; MTX and CYA were administered at standard doses as GVHD prophylaxis. His identical donor was mobilised with subcutaneous filgrastim, 5 g/kg/day/5 days (total dose 25 g/kg); PBSC were collected on days 5 and 6 with the resultant product containing 12 × 10 8 MNC/kg. The PBSC donor had previously donated PRBCs and apheresis platelets for the patient. Engraftment was documented by day +11 when he reached an ANC Ͼ500/l, by day +15 his platelet count was Ͼ20 000/l. He was discharged on day +18. A year later the patient remains free of disease with a normal blood count. Transfusion-related haemochromatosis, with a pretransplant serum ferritin concentration of 2700 g/l, has been treated with therapeutic phlebotomy; currently he has normal liver function tests.
Case 4
A 28-year-old female, diabetic and hypertensive, developed pancytopenia in November 1997. Her BMA showed SAA with no cytogenetic changes. She had received multiple transfusions due to rapid development of platelet refractoriness, with no response to HLA-matched platelets. As a result of her thrombocytopenia she suffered a subdural haemorrage, without subsequent neurological deficit. The patient was initially treated with ATG but quickly developed an adverse reaction including hypertension, tachycardia and abnormal liver function tests, which led to ATG being suspended. A fully compatible brother was mobilised with subcutaneous G-CSF at a total dose of 25 g/kg before collection. After conditioning exclusively with Cy, 50 mg/kg/4 days (total dose 200 mg/kg), the patient received a PBSCT at a dose of 15 × 10 8 MNC/kg. CYA plus MTX were administered as GVHD prophylaxis. The post-transplant course was uncomplicated and full engraftment was documented by day +11, when she reached an ANC count Ͼ500/l; platelets rose to over 20 000/l on day +14, being discharged on day +16. Ten months later she is free of transfusion requirements, with no evidence of GVHD and a normal blood count.
Discussion
Survival after transplantation for AA is best in patients who receive grafts before exposure to transfusion of blood products with its subsequent sensitisation to histocompatibility antigens, 9 since in this circumstance conditioning with Cy alone can be sufficient to suppress host immunity and graft rejection is unusual. Although numbers have declined over the past two decades, GF still occurs in a significant number of patients after allogeneic BMT and has been associated with transfusion-induced sensitisation and a low marrow dose, among other factors. 10 In multitransfused patients with AA who received immunosuppression with Cy alone, the rate of GF was 37% in the 1970s, but it has now been reduced to less than 10% 3 by the use of high-dose stem cell transplant, avoidance of transfusions prior to BMT and additional immunosuppression with ATG and CYA. 1, 2 A target collection equal to or greater than 2 × 10 6
CD34
+ cells/kg has been suggested to ensure haematopo-ietic reconstitution, 11 although a recently published study concludes that a dose of only 0.75 × 10 6 /kg of CD34 + PBSC guarantees haematopoietic recovery within a reasonable number of days. 12 The same study concludes that a minimum of 5 CD34
+ MNC cells/l in the peripheral blood of the donor, before apheresis, most probably ensures the adequate collection of enough progenitor cells for transplantation.
Although we did not count CD34 + cells, either in the donor or the PBSC product, we infused an average of 13.5 × 10 8 MNC/kg; a dose Ͼ6 × 10 8 MNC/kg has been published as an adequate number. 13 Other studies, however, suggest a lower figure of 3 × 10 8 MNC/kg to predict engraftment.
14 Factors significantly associated with rejection among multitransfused patients given Cy are a low marrow cell dose (less than 3 × 10 8 marrow cells/kg body weight), and a positive in vitro test for cell-mediated immunity of recipient vs donor cells, consistent with the concept of transfusion-induced sensitisation. 10, 11 Based on the evidence that larger marrow cell doses are accompanied by a lower rate of graft rejection, 15 and previous successful experiences of SAA cases transplanted with PBSC, 14, 16 we decided to use PBSCT instead of BMT in these SAA patients, to take advantage of the high number of stem cells that this procedure can provide. 12 In general, allogeneic PBSC grafts contain three to four times more CD34 + cells and one to two logs more T cells than BM grafts. 17 A positive effect has also been attributed to donor CD8 + lymphocytes as playing a pivotal role in preventing allogeneic marrow rejection. Probable mechanisms are the induction of cytotoxic effectors needed to eliminate recipient T cells remaining after the pretransplant conditioning regimen, or the production of cytokines needed to support the growth and differentiation of haematopoietic stem cells. 18 Presumed advantages of using mobilised PBSCs rather than BM include a rapid haematologic recovery and an earlier immune system reconstitution; 7 an increased risk of chronic GVHD after primary allogeneic PBSCT has been reported, 19 although none of our patients developed this complication. Our first two patients suffered a GF after BMT and were rescued by a PBSCT containing on the average 3.75 times as many MNC as those in the BM infusion. The last two patients received a PBSCT as their first transplant option, with no ATG included in the conditioning regimen, with remarkably good results. It is important to note that the PBSC donor in case number 3 was his brother, who previously had served as a blood and apheresis platelet donor, with no obvious adverse effect on transplant outcome. Any degree of sensitisation to transplant antigens could have been overcome by the large dose of stem cells in the PBSC graft.
We conclude that the principal factors in the excellent outcome of nonmyeloablative PBSCT in these patients were the high dose of stem cells provided in the PBSC graft, which suggests that increasing the number of cells, even without increasing the conditioning dosage, can be sufficient to overcome sensitisation in multitransfused immunised patients or after a first-graft rejection, and the administration of MTX + CYA in the post-engraftment regimen. The probability that the large number of lymphocytes contained in the PBSC grafts constitutes the decisive factor for better engraftment should also be considered.
Recently published retrospective experience with a large number of SAA patients over 26 years, found that the 10-year probability of survival after second bone marrow transplants for graft rejection has increased from 5% to 83% during this period of time. Multivariate analysis showed MTX plus CYA prophylaxis to be a significant factor accounting for this increase in patient survival after a second BMT. 5 No similar data are yet available for PBSCT in SAA.
More studies are required to define the contribution of the high dose of stem cells in PBSCT, its ideal number and possible role in overcoming HLA sensitisation, and to determine the importance of the conditioning and postgrafting regimens to avoid GF in multitransfused patients with SAA. It will also be necessary to elucidate the suggested positive role of the high number of T cells infused with the PBSC graft in the avoidance of GF. 18 
